Published studies of bladder cancer risk in subjects treated with cyclophosphamide
| Diagnosis | Patients (n) | Cumulative dose of CY for patients (g) Median (range) | Bladder cancers (n) | Relative risk | Cumulative risk (follow up) | Reference |
|---|---|---|---|---|---|---|
| CY, cyclophosphamide; NHL, non-Hodgkin’s lymphoma; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, Wegener’s granulomatosis. | ||||||
| * and ** indicate studies with overlapping or identical study groups. | ||||||
| NHL | 6171 | 37 (9–146) | 9 | 4.5 | Not stated | Travis et al (1995)4 |
| NHL | 471 | 104 (27–148) | 7 | 6.8 | 3.5% (8 yrs) 11% (12 yrs) | Pedersen-Bjergaard et al (1988)5 |
| SLE | 1585 | Not stated | 5 | 1.6 | Not stated | Mellemkjaer et al (1997)21 |
| SLE/RA | 43/11 | 46/56 (2–152) | 1/1 | Not stated | Not stated | Plotz et al (1979)6 |
| RA | 119 | 63 (18–108) | 6 | 5% (11 yrs) | Baker et al (1987)22 * | |
| RA | 119 | 120 (mean dose) | 9 | 22 | Not stated | Radis et al (1995)23 * |
| MS | 70 | 61 (38–93) | 5 | 5.7% (not stated) | de Ridder et al (1998)24 | |
| WG | 145 | 144 (19–251) | 7 | 31 | 5% (10 yrs) | Talar-Williams (1996)1 ** |
| WG | 158 | Not stated | 4 | 33 | Not stated | Hoffman et al (1992)2 ** |
| WG | 111 | 101 (5–531) | 3 | 2.7% (20 yrs) | Stillwell et al (1988)25 | |
| WG | 1065 | 113 (0–234) | 11 | 4.8 | 10% (16 yrs) | Present study |